Understanding Inovio Stock Symbol and Its Financials

Inovio Pharmaceuticals' stock symbol is INO. This symbol is used to represent the company's shares on various stock exchanges, including the NASDAQ.

The company's financials are publicly available and can be accessed through various online platforms, such as Yahoo Finance or Google Finance. These platforms provide real-time data on INO's stock price, trading volume, and other key financial metrics.

Inovio Pharmaceuticals is a biotechnology company focused on developing innovative vaccines and immunotherapies. The company's research and development efforts are concentrated on creating treatments for a range of diseases, including infectious diseases and cancer.

INO's financial performance has been impacted by the COVID-19 pandemic, with the company experiencing increased expenses related to vaccine development and clinical trials.

Consider reading: Inovio Stock Quote

As you explore the financial performance of Inovio, it's essential to understand the company's trailing total returns. Trailing total returns as of 10/8/2025, which may include dividends or other distributions, are a key metric to consider.

The benchmark for Inovio's performance is the S&P 500 (^GSPC).

Inovio's financial performance has been a mixed bag. The company reported a net loss of $146.8 million in 2020, which is a significant increase from the net loss of $112.5 million in 2019.

Inovio's revenue has been driven by its collaborations and licensing agreements with other companies. For example, the company received $3.5 million in revenue from its collaboration with the Bill and Melinda Gates Foundation in 2020.

The company's operating expenses have been a major contributor to its net loss. In 2020, Inovio's operating expenses totaled $171.4 million, which is a significant increase from the $123.5 million in operating expenses in 2019.

Inovio's cash and cash equivalents have been a key factor in its ability to fund its operations. As of December 2020, the company had $434.8 million in cash and cash equivalents.

The company's stock price has been volatile, with a high of $22.50 in 2020 and a low of $1.57 in 2021.

Consider reading: Cash App Stock Symbol

Let's take a closer look at Inovio's profitability. The company's Return on Assets (Normalized) is a staggering -72.79%. That's a significant negative return, indicating the company is struggling to generate profits from its assets.

The Return on Equity (Normalized) is also heavily in the red, at -102.71%. This suggests that even the shareholders are not seeing a positive return on their investment.

In contrast, ACLX has a relatively healthy Return on Assets (Normalized) of 0.51%. This indicates that the company is able to generate a positive return from its assets.

Here's a comparison of the three companies' Return on Assets (Normalized) metrics:

JANX's Return on Assets (Normalized) is -5.15%, which is a significant improvement over INO's -72.79%. However, it's still a negative return, indicating the company is not generating enough profits from its assets.